IL296487A - Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19 - Google Patents

Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19

Info

Publication number
IL296487A
IL296487A IL296487A IL29648722A IL296487A IL 296487 A IL296487 A IL 296487A IL 296487 A IL296487 A IL 296487A IL 29648722 A IL29648722 A IL 29648722A IL 296487 A IL296487 A IL 296487A
Authority
IL
Israel
Prior art keywords
antibody
seq
covid
patients
nos
Prior art date
Application number
IL296487A
Other languages
English (en)
Hebrew (he)
Original Assignee
Biocon Ltd
Centro De Inmunolog?A Molecular
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CU2020000027A external-priority patent/CU20200027A7/es
Application filed by Biocon Ltd, Centro De Inmunolog?A Molecular filed Critical Biocon Ltd
Publication of IL296487A publication Critical patent/IL296487A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL296487A 2020-04-04 2021-04-03 Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19 IL296487A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202041014994 2020-04-04
CU2020000027A CU20200027A7 (es) 2020-04-17 2020-04-17 Uso de anticuerpos monoclonales anti-cd6 no depletantes en el tratamiento de la tormenta de citocinas
PCT/IB2021/052793 WO2021199006A1 (en) 2020-04-04 2021-04-03 Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19

Publications (1)

Publication Number Publication Date
IL296487A true IL296487A (en) 2022-11-01

Family

ID=77928142

Family Applications (1)

Application Number Title Priority Date Filing Date
IL296487A IL296487A (en) 2020-04-04 2021-04-03 Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19

Country Status (15)

Country Link
US (1) US20230151107A1 (cg-RX-API-DMAC7.html)
EP (1) EP4126961A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023526890A (cg-RX-API-DMAC7.html)
KR (1) KR20220165267A (cg-RX-API-DMAC7.html)
CN (1) CN115698071A (cg-RX-API-DMAC7.html)
AU (1) AU2021247258A1 (cg-RX-API-DMAC7.html)
BR (1) BR112022018936A2 (cg-RX-API-DMAC7.html)
CA (1) CA3174566A1 (cg-RX-API-DMAC7.html)
CL (1) CL2022002684A1 (cg-RX-API-DMAC7.html)
CO (1) CO2022014199A2 (cg-RX-API-DMAC7.html)
IL (1) IL296487A (cg-RX-API-DMAC7.html)
MX (1) MX2022012229A (cg-RX-API-DMAC7.html)
TW (1) TW202200202A (cg-RX-API-DMAC7.html)
WO (1) WO2021199006A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202210032B (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2993186T (pt) 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
IL266087B2 (en) * 2016-10-18 2024-02-01 Biocon Ltd Use of itolizumab to reduce phosphorylation of cd6
WO2025149667A1 (en) 2024-01-12 2025-07-17 Pheon Therapeutics Ltd Antibody drug conjugates and uses thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CU22584A1 (es) * 1995-11-17 1999-11-03 Centro Inmunologia Molecular Composiciones farmacéuticas que contienen un anticuerpo monoclonal que reconoce el antígeno de diferenciación leucocitario humano cd6 y sus usos para el diagnóstico y tratamiento de la psoriasis
PT2993186T (pt) * 2008-03-14 2019-11-29 Biocon Ltd Anticorpo monoclonal e um método do mesmo
KR20110091780A (ko) * 2008-11-25 2011-08-12 앨더 바이오파마슈티컬즈, 인코포레이티드 악액질, 쇠약, 피로 및/또는 발열을 예방하거나 치료하는 il­6의 길항제
EP3448874A4 (en) * 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
US10562975B2 (en) * 2016-06-15 2020-02-18 The Regents Of The University Of Michigan CD6 antibody for treatment of T-cell mediated diseases or disorders
WO2019169015A1 (en) * 2018-02-27 2019-09-06 Equillium, Inc. Anti cd6 antibodies for treating severe asthma
AU2020415307A1 (en) * 2019-12-24 2022-06-09 F. Hoffmann-La Roche Ag Method of treating virus infection using a TLR7 agonist

Also Published As

Publication number Publication date
JP2023526890A (ja) 2023-06-26
BR112022018936A2 (pt) 2022-12-06
WO2021199006A1 (en) 2021-10-07
ZA202210032B (en) 2024-09-25
EP4126961A4 (en) 2024-07-17
CN115698071A (zh) 2023-02-03
TW202200202A (zh) 2022-01-01
AU2021247258A1 (en) 2022-11-10
KR20220165267A (ko) 2022-12-14
US20230151107A1 (en) 2023-05-18
EP4126961A1 (en) 2023-02-08
MX2022012229A (es) 2022-10-27
CA3174566A1 (en) 2021-10-07
CO2022014199A2 (es) 2022-11-08
CL2022002684A1 (es) 2023-03-24

Similar Documents

Publication Publication Date Title
US11344545B2 (en) Use of levocetirizine and montelukast in the treatment of autoimmune disorders
BR112021005580A2 (pt) usos de éster etílico de ácido eicosapentaenoico (e-epa) para reduzir o risco de eventos cardiovasculares em um indivíduo
IL296082A (en) Methods for treating coronavirus infection and resulting inflammation-induced lung injury
US11052073B1 (en) Sphingosine kinase 2 inhibitor for treating coronavirus infection
CN116261463A (zh) 治疗痛风的方法
US20230151107A1 (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
IL297334A (en) Eclitasertib for use in the treatment of disorders associated with systemic hyperinflammatory responses
CN119564834A (zh) 度拉糖肽的治疗用途
IL295040A (en) Treatment of coronavirus infection with interferon lambda
RU2828013C1 (ru) Композиции антител к cd6 и способы лечения и снижения негативных последствий коронавируса, включая covid-19
Cnossen et al. Spontaneous Sublingual Haematoma in a 90-year Old Patient: A Complication of Direct Oral Anticoagulants
HK40078901A (en) Anti-cd6 antibody compositions and methods for treating and reducing negative effects of a coronavirus including covid-19
EP4137144A2 (en) Peptide for the treatment of cytokine storm syndrome
RU2834279C1 (ru) Пептид для лечения синдрома цитокинового шторма
EP4153310B1 (en) Bbeta-15-42 for the treatment of viral endothelitis
RU2837859C1 (ru) Лечение коронавирусной инфекции
Yahya et al. Old drug with new milestone: chloroquine and hydroxychloroquine in SARS-COV-2 (COVID-19) with multifaceted effects in other diseases
Golzari-Sorkheh et al. Alzheimer’s Disease and COVID-19 Pathogenic Overlap: Implications for Drug Repurposing
Spiegler Site of Central Venous Catheterization: Does It Matter?
Schnell New cardiovascular, kidney, and metabolic outcomes Republished under CC BY 4.0. Originally published in Cardiovasc Diabetol 2025; 24 (1): 187. doi: 10.1186/s12933-025-02700-0
BR122024013593A2 (pt) Usos terapêuticos de dulaglutida